ARA-290
$78.00
Skip to product information
ARA-290
$78.00
ARA 290 (Cibinetide) — 11-Amino-Acid Erythropoietin-Derived Tissue-Repair Peptide
ARA 290 is a synthetic 11-amino-acid peptide derived from the “helix B surface” region of Erythropoietin (EPO). It is engineered to activate the so-called “innate repair receptor” (IRR) complex (EPOR/β-common subunit) which triggers anti-inflammatory, cytoprotective and repair pathways — **without** stimulating red-blood-cell production.
Identifiers
- Synonym: Cibinetide (also known as HBSP = Helix B Surface Peptide)
- CAS No: 1208243-50-8
- Sequence (approx): pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa)
- MW (≈): ~1,257 Da
How It Works (Plain English)
- Rather than act like EPO on red-blood-cells, ARA 290 selectively activates the **IRR** on tissue-repair/immune cells.
- This triggers signals that reduce inflammation, protect cells from damage (anti-apoptosis), support nerve-repair and endothelial function. [oai_citation:6‡Frontiers]
- Because it bypasses the erythropoietic effects of EPO, it is explored in research for neuropathy, metabolic dysfunction, ischemia-injury and repair models.
Why Researchers Use It
- To explore **nerve-repair** and **small-fiber neuropathy** in preclinical and human models.
- To study **metabolic/inflammation cross-talk** (diabetes, lipids, tissue injury) via IRR activation. [oai_citation:9‡PubMed]
- To model **tissue protection and repair-enhancement** (ischemia, aging, vascular injury) in animal systems.
Key Studies — What Was Tested, What Changed, Why It Matters
Neuropathy Pilot Trial in Sarcoidosis Patients
- What was tested: Patients with Sarcoidosis-associated small-fiber neuropathy (SFN) treated with ARA 290 (2 mg, IV, three times weekly for 4 weeks) vs placebo.
- What changed: Significant improvement in SFNSL (Small Fibre Neuropathy Screening List) score and physical functioning (SF-36), no major safety issues.
- Why it matters: Demonstrates translational potential for peptide-mediated neuro-repair and anti-inflammation in human nervous-system injury.
Type 2 Diabetes & Neuropathy Study
- What was tested: Adults with type 2 diabetes and neuropathic symptoms given ARA 290 (4 mg SC daily for 28 days) then followed 28 days more.
- What changed: Improvements in HbA1c, HDL/triglyceride profiles, neuropathic-symptom questionnaires and corneal nerve-fiber density vs placebo.
- Why it matters: Supports the idea that IRR-activating peptides can impact metabolic & nerve outcomes simultaneously.
Aging & Cardiac Repair Animal Study
- What was tested: Older mice treated with ARA 290 to assess cardiac structure/function, inflammation and frailty.
- What changed: Reduced age-associated blood pressure increases, preserved left-ventricular ejection fraction, lower systemic inflammatory markers.
- Why it matters: Expands potential from neuropathy to systemic repair/anti-inflammation in aging and cardiovascular research.
Potential Research Applications
Nerve-Repair & Neuropathy
- Small-fiber neuropathy (SFN), diabetic neuropathy models
- Corneal nerve-fiber density, intra-epidermal nerve-fibre assays, pain behavior
Metabolism & Inflammation
- HbA1c, lipid profiles, insulin-resistance models
- Inflammatory cytokines (TNF-α, IL-1β), microglia/astrocyte activation
Tissue Protection / Aging / Ischemia
- Ischemia-reperfusion, vascular injury, aging models, organ function (heart, kidney)
- Cell survival endpoints (apoptosis, caspases), barrier/endothelial integrity
Synergistic Peptides (for Study Design)
GHK-Cu
- Why pair: ECM/tissue-repair gene programs, complements ARA 290’s anti-inflammation & repair axis.
- Angle: Gene-expression arrays (NGF/BDNF, ECM) + nerve-fiber density metrics.
TB-500 (Thymosin-β4 fragment)
- Why pair: Cytoskeletal/angiogenic repair focus; useful in models of vascular/nerve repair alongside IRR activation.
- Angle: Endothelial sprouting + nerve regeneration assays.
Tα1 (Thymosin-α1)
- Why pair: Immune-modulation/anti-inflammation; complements ARA 290’s anti-inflammatory repair focus.
- Angle: Cytokine panels + histologic nerve/vascular repair endpoints.
Design Notes
- Clearly define vehicle, salt/form, dosing schedule (daily vs alternate day) in multi-week models.
- Document baseline nerve metrics (e.g., IENF, CNFD) and blind assessment where possible.
Known Concerns (Context)
- Clinical evidence, but limited long-term data:
- Short half-life & delivery:
- Research use only:
Specifications & Handling
- Form: Lyophilized peptide powder (lot-coded) — verify independent COA.
- Purity: Typically ≥ 99 % (HPLC/MS verified) in research-grade peptides.
- Storage: ≤ −20 °C; protect from light/moisture; minimize freeze–thaw cycles.
- In solution:
- Packaging: Tamper-evident; labeled “research use only.”
Regulatory & Use Notice
Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.